Balaji Amines Limited
Balaji Amines Ltd specialises in manufacturing Methylamines, Ethylamines, Derivatives of specialty chemicals and Pharma Excipients. These have been the main products, it also have facilities for the manufacturing of derivatives, which are down-stream products for various pharma/pesticide industries apart from user specific requirements. It is one of the largest manufacturers of aliphatic amines in India.
What Balaji files
- Others52
- Investor Meet24
- Updates16
- Important12
- Board Meeting11
- PPTs9
Balaji Amines reported strong Q1FY27 consolidated results: Revenue ₹461 Cr, EBITDA ₹121 Cr, PAT ₹78 Cr. Successfully commissioned India's first 100,000 TPA DME plant. Expansions of NMM, ACN, and Balaji Specialty Chemicals (₹750 Cr mega project) are progressing for FY27 commissioning.
Balaji Amines reported Q4FY26 consolidated revenue of ₹403 Cr, EBITDA ₹102 Cr, and PAT ₹65 Cr. New projects including DME, NMM, Acetonitrile, and a ₹750 Cr subsidiary expansion are underway, funded internally. The company remains standalone debt-free, showing resilience amidst operational disruptions.
Balaji Amines has approved financial results for the year. Consolidated revenue was ₹1424.98 Cr, with profit at ₹169.16 Cr. The board also proposed a final dividend of ₹11 per equity share (550% on ₹2 FV).
Balaji Amines is gradually restarting production of ammonia-based products like Methylamines and Ethylamines. This follows improving global ammonia supply, which was previously disrupted by geopolitical conflict. The company is actively seeking alternative suppliers for long-term stability.
Balaji Amines reports the resignation of Mr. Laxman Vishnudas Limkar, its Senior Assistant General Manager and Factory Manager, citing personal reasons. This marks a change in the company's senior operational management.